Effect of the introduction of the monovalent rotavirus vaccine on hospitalisations in Kenya

February 14, 2020

Share article

The monovalent rotavirus vaccine, Rotarix, was introduced in Kenya in July 2014 and is recommended for infants at ages 6 and 10 weeks. The authors conducted hospital-based surveillance in two population-based sites to assess the impact of the vaccine on the incidence of rotavirus-associated hospitalisations (RVH). They examined acute diarrhoea hospitalisations among children aged <5 years. Between 2010 and 2017, there were 1513 and 1652 diarrhoea hospitalisations in Kilifi and Siaya, respectively. Among those tested for rotavirus, 28% and 23% were positive. There was a 57% reduction in RVH observed in the first year post-vaccine introduction in Kilifi and a 59% reduction in Siaya. In the second year, RVH decreased further at both sites; 80% reduction in Kilifi and 82% reduction in Siaya, with this reduction being sustained at both sites into the third year. Therefore a substantial reduction of RVH and all-cause diarrhoea was seen in two demographic surveillance sites in Kenya within 3 years of vaccine introduction.

Read more here

Otieno GP, Bottomley C, Khagayi S, Adetifa I, Ngama M, et al. ISSN: Clin Infect Dis; pii: ciz912


Added: February 14, 2020